Yara Banz

2.8k total citations
110 papers, 1.7k citations indexed

About

Yara Banz is a scholar working on Surgery, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Yara Banz has authored 110 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Surgery, 28 papers in Pathology and Forensic Medicine and 23 papers in Oncology. Recurrent topics in Yara Banz's work include Lymphoma Diagnosis and Treatment (20 papers), Acute Myeloid Leukemia Research (11 papers) and Organ and Tissue Transplantation Research (10 papers). Yara Banz is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Acute Myeloid Leukemia Research (11 papers) and Organ and Tissue Transplantation Research (10 papers). Yara Banz collaborates with scholars based in Switzerland, United States and Germany. Yara Banz's co-authors include Robert Rieben, Simon C. Robson, Thomas Pabst, Guido Beldi, Ulrike Bacher, Radu Olariu, Urban Novak, Esther Vögelin, Otto M. Hess and Adrian F. Ochsenbein and has published in prestigious journals such as Journal of Clinical Investigation, Nature Medicine and Nature Communications.

In The Last Decade

Yara Banz

102 papers receiving 1.7k citations

Peers

Yara Banz

SURGE

IMMUN

ONCOL

PFM

Debra A. Hullett United States

Cécile Holweg United States

Maria T. Millan United States

Jikun Shen United States

Iris Bittmann Germany

Evan A. Farkash United States

Jun Hirose Japan

Roberta Gualtierotti Italy

Déla Golshayan Switzerland

Michael Burg Netherlands

Debra A. Hullett United States

Yara Banz

873 ×1.9

SURGE

376 ×0.9

IMMUN

530 ×1.7

127 ×0.5

ONCOL

265 ×1.3

PFM

Citations per year, relative to Yara Banz Yara Banz (= 1×) peers Debra A. Hullett

Countries citing papers authored by Yara Banz

Since Specialization

Citations

This map shows the geographic impact of Yara Banz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yara Banz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yara Banz more than expected).

Fields of papers citing papers by Yara Banz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yara Banz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yara Banz. The network helps show where Yara Banz may publish in the future.

Co-authorship network of co-authors of Yara Banz

This figure shows the co-authorship network connecting the top 25 collaborators of Yara Banz. A scholar is included among the top collaborators of Yara Banz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yara Banz. Yara Banz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hoffmann, Michèle J., Uyen Huynh‐Do, Yara Banz, et al.. (2025). Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis. Hematological Oncology. 43(4). e70120–e70120. 1 indexed citations

Akhoundova, Dilara, et al.. (2025). Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma. Cancers. 17(8). 1297–1297.

Zhang, Lei, et al.. (2024). Immune Rejection of Cartilage in a Swine Vascularized Composite Allotransplantation Model. Transplantation Proceedings. 56(8). 1896–1903. 2 indexed citations

Zhang, Lei, Yara Banz, Stefanie Hirsiger, et al.. (2024). Transcriptome profiling of immune rejection mechanisms in a porcine vascularized composite allotransplantation model. Frontiers in Immunology. 15. 1390163–1390163. 3 indexed citations

Hoffmann, Michèle J., Yara Banz, Jörg Halter, et al.. (2024). True Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Considerations—Brief Report. Current Oncology. 31(4). 2067–2075.

Andres, Martin, Gertrud Wiedemann, Sacha Zeerleder, et al.. (2023). Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematological Oncology. 41(5). 912–921. 9 indexed citations

Bacher, Ulrike, Michèle J. Hoffmann, Urban Novak, et al.. (2023). Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma. Cancers. 15(7). 2091–2091.

Seipel, Katja, et al.. (2023). Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma. Current Oncology. 30(12). 10463–10476. 3 indexed citations

Rausch, Christian, Ulrike Bacher, Manuela Rabaglio, et al.. (2022). Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study. Journal of Clinical Medicine. 11(18). 5378–5378. 2 indexed citations

10.

Shumilov, Evgenii, Martin S. Zinkernagel, Naomi Porret, et al.. (2022). Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology. Current Oncology. 29(2). 766–776. 3 indexed citations

11.

Bacher, Ulrike, et al.. (2022). Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers. 15(1). 44–44. 4 indexed citations

12.

Bacher, Ulrike, et al.. (2022). BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study. Journal of Clinical Medicine. 11(13). 3748–3748. 2 indexed citations

13.

Seipel, Katja, Yara Banz, Gertrud Wiedemann, et al.. (2022). Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. Cancers. 14(10). 2516–2516. 26 indexed citations

14.

Förster, Stefan, Yara Banz, Justine Brodard, et al.. (2021). Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes. Cancers. 13(22). 5712–5712. 6 indexed citations

15.

Novak, Urban, et al.. (2021). Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers. 13(23). 6073–6073. 18 indexed citations

16.

Bacher, Ulrike, et al.. (2020). Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation. Hematological Oncology. 39(1). 97–104. 10 indexed citations

17.

Murone, Maximilien, Ramin Radpour, Antoine Attinger, et al.. (2017). The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells. Molecular Cancer Therapeutics. 16(8). 1497–1510. 12 indexed citations

18.

Weber, Benjamin, Silvia Rihs, Stefan Freigang, et al.. (2016). TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nature Communications. 7(1). 13151–13151. 79 indexed citations

19.

Mager, Lukas F., Carsten Riether, Christian M. Schürch, et al.. (2015). IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. Journal of Clinical Investigation. 125(7). 2579–2591. 73 indexed citations

20.

Banz, Yara, Guido Beldi, Yan Wu, et al.. (2008). CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. British Journal of Haematology. 142(4). 627–637. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact